This article provides a transparent description of Mreg_UKR cell products, including manufacture and quality-control processes, using the structure and vocabulary of the 'Minimum Information about Tolerogenic Antigen-presenting Cells' reporting guidelines. This information is intended as a resource for those in the field, as well as a stimulus to develop a new wave of immunoregulatory and tissue-reparative monocyte-derived cell therapies.
Keywords: Mreg; cell-based therapy; minimum information about tolerogenic antigen-presenting cells; monocyte; regulatory macrophage; solid organ transplantation; suppressor macrophage; tolerogenic antigen presenting cell (APC).
© 2017 Steunstichting ESOT.